Pharmacogenetic Influence of GST Polymorphisms on Anthracycline-Based Chemotherapy Responses and Toxicity in Breast Cancer Patients: A Multi-Analytical Approach

[1]  B. Mittal,et al.  Influence of ABCB1 genetic variants in breast cancer treatment outcomes. , 2013, Cancer epidemiology.

[2]  P. Bajpai,et al.  Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients , 2011, Surgery Today.

[3]  G. Hortobagyi,et al.  Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer , 2010, Clinical Cancer Research.

[4]  G. Hortobagyi,et al.  Glutathione-S-Transferase-Pi Expression in Early Breast Cancer: Association With Outcome and Response to Chemotherapy , 2010, Cancer investigation.

[5]  A. Levine,et al.  Germline Mutations and Polymorphisms in the Origins of Cancers in Women , 2010, Journal of oncology.

[6]  M. Parmar,et al.  Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Hou,et al.  Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC Highly Correlated with Early Relapse of Breast Cancer Patients in Taiwan , 2008, Annals of Surgical Oncology.

[8]  T. Aoki,et al.  Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. , 2008, Genetics and molecular research : GMR.

[9]  M. Romkes,et al.  Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. , 2006, British journal of clinical pharmacology.

[10]  D. Townsend,et al.  The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.

[11]  S. Ahmed,et al.  Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma , 2003, British Journal of Cancer.

[12]  P. Tan,et al.  Prognostic Significance of Glutathione S-Transferase-Pi in Invasive Breast Cancer , 2003, Modern Pathology.

[13]  Jason H. Moore,et al.  Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions , 2003, Bioinform..

[14]  W James Gauderman,et al.  Sample size requirements for matched case‐control studies of gene–environment interaction , 2002, Statistics in medicine.

[15]  C. Akyerli,et al.  Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population , 2001, Archives of Toxicology.

[16]  K. Kang,et al.  Glutathione S-Transferase Mu Modulates the Stress-activated Signals by Suppressing Apoptosis Signal-regulating Kinase 1* , 2001, The Journal of Biological Chemistry.

[17]  D. Harpole,et al.  The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  D. Phillips,et al.  Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. , 2000, Cancer research.

[19]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[20]  Yoshiharu Saito,et al.  Significance of Multi‐Drug‐Resistant Proteins in Predicting Chemotherapy Response and Prognosis in Epithelial Ovarian Cancer * , 1999, The journal of obstetrics and gynaecology research.

[21]  B. Trock,et al.  Prognostic Value of p53, Glutathione S-Transferase π, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer , 1999 .

[22]  S. Lizard-Nacol,et al.  Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer , 1999, Breast Cancer Research.

[23]  P. Johnston,et al.  Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  J. Buolamwini,et al.  Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S-Transferase Pi Gene Variants , 1997, The Journal of Biological Chemistry.

[25]  R. Perry,et al.  Glutathione levels and variability in breast tumors and normal tissue , 1993, Cancer.

[26]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[27]  P. Vrignaud,et al.  Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture. , 1986, Pharmacological research communications.

[28]  Dianke Yu,et al.  Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. , 2011, Chinese medical journal.

[29]  Xiaohui Zhang,et al.  Effects of Stereo-staged Combustion Technique on NOx Emmision Charactisctics , 2009 .

[30]  X. Shu,et al.  Genetic polymorphisms in glutathione‐S‐transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma , 2005, Cancer.

[31]  F. Pannuti,et al.  Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients , 2004, Cancer Chemotherapy and Pharmacology.

[32]  N. Hamajima,et al.  Allele Frequencies of 25 Polymorphisms Pertaining to Cancer Risk for Japanese, Koreans and Chinese. , 2002, Asian Pacific journal of cancer prevention : APJCP.

[33]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[34]  B. Trock,et al.  Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  T. Tephly,et al.  The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[36]  R. Armstrong,et al.  Structure, catalytic mechanism, and evolution of the glutathione transferases. , 1997, Chemical research in toxicology.